Role of endogenous cardiotonic steroids in sodium homeostasis

Nephrology Dialysis Transplantation

Volumn 23, Issue 9, 2008, Pages 2723-2729

  Schoner, Wilhelm ^a   Scheiner Bobis, Georgios ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Arterial hypertension; Cardiomyopathy; Endogenous cardiotonic steroids; Marinobufagenin; Ouabain

Indexed keywords

MARINOBUFAGENIN; OUABAIN; STEROID; TELOCINOBUFAGIN; UNCLASSIFIED DRUG;

ADRENAL CORTEX; ARTICLE; CARDIOMYOPATHY; HORMONAL REGULATION; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; HYPERTENSION; KIDNEY PROXIMAL TUBULE; NATRIURESIS; NONHUMAN; PRIORITY JOURNAL; SODIUM BALANCE; SODIUM INTAKE; SODIUM TRANSPORT; UREMIA;

ADRENAL CORTEX; ANIMALS; BUFANOLIDES; CARDIAC GLYCOSIDES; CARDIOTONIC AGENTS; DIGOXIN; HOMEOSTASIS; HUMANS; HYPERTENSION; KIDNEY TUBULES, PROXIMAL; NATRIURESIS; OUABAIN; SODIUM; SODIUM-POTASSIUM-EXCHANGING ATPASE; VASOCONSTRICTOR AGENTS;

EID: 58149225539     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn325     Document Type: Article

References (98)

1. de Wardener HE, MacGregor GA. Sodium and blood pressure. Curr Opin Cardiol 2002; 17: 360-367
2. Ritz E, Dikow R, Morath C et al. Salt - a potential 'uremic toxin'? Blood Purif 2006; 24: 63-66
3. Frohlich ED. The Salt Conundrum: a hypothesis. Hypertension 2007; 50: 161-166
4. Haddy F, Pamnani M. Role of dietary salt in hypertension. J Am Coll Nutr 1995; 14: 428-438
5. x sodium channels for the control of salt-intake behavior. J Neurosci 2004; 24: 9276-9281
6. Buckalew VM, Haddy FJ. Circulating natriuretic factors in hypertension. In Laragh JH, Brenner EM (eds). Hypertension: Pathophysiology, Diagnosis and Management. New York: Raven Press, 1990, 939-954
7. DeWardener HE, Clarkson EM. Concept of natriuretic hormone. Physiol Rev 1985; 65: 658-759
8. +-ATPase alterations in ouabain and adducin-dependent hypertension. Am J Physiol Regul Integr Comp Physiol 2006; 290: R529-R535
9. Schoner W, Scheiner-Bobis G. Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth. Am J Physiol Cell Physiol 2007; 293: C509-C536
10. Haddy FW, Overbeck HW. The role of humoral agents in volume expanded hypertension. Life Sci 1976; 19: 935-948
11. Blaustein MP Sodium ions, calcium ions, blood pressure regulation and hypertension: a reassessment and a hypothesis. Am J Physiol 1977; 232: C167-C173
12. McGrath M, de Bold M, de Bold A. The endocrine function of the heart. Trends Endocrinol Metab 2005; 16: 469-477
13. Haddy FJ. Role of dietary salt in hypertension. Life Sci 2006; 79: 1585-1592
14. +-ATPase associated with essential hypertension. Nature 1982; 300: 650-652
15. Moreth K, Kuske R, Renner D et al. Blood pressure in essential hypertension correlates with the concentration of a circulating inhibitor of the sodium pump. Klin Wochenschr 1986; 64: 239-244
16. Poston L, Sewell R, Wilkinson S et al. Evidence for a circulating sodium transport inhibitor in essential hypertension. Brit Med J 1981; 282: 847-849
17. Ringer S. Regarding the influence of the organic constituents of the blood on the contractility of the ventricle. J Physiol 1885; 6: 361-381
18. Szent-Györgyi A. Chemical Physiology of Contraction in Body and Heart Muscle. New York: Academic Press, 1953, 86-91
19. Schoner W, Scheiner-Bobis G. Endogenous and exogenous cardiac glycosides and their mechanisms of action. Am J Cardiovasc Drugs 2007; 7: 173-189
20. Blaustein MP, Zhang J, Chen L et al. How does salt retention raise blood pressure? Am J Physiol Regul Integr Physiol 2006; 290: 514-523
21. Nesher M, Shpolansky U, Rosen H et al. The digitalis-like steroid hormones: new mechanisms of action and biological significance. Life Sci 2007; 80: 2093-2107
22. Schatzmann HJ. Herzglykoside als Hemmstoffe für den aktiven Kalium- und Natriumtransport durch die Erythrocytenmembran. Helv Physiol Pharmacol Acta 1953; 11: 346-354
23. Hamlyn JM, Blaustein MP, Bova S et al. Identification and characterization of a ouabain-like compound from human plasma. Proc Natl Acad Sci 1991; 88: 6259-6263
24. Schneider R, Wray V, Nimtz M et al. Bovine adrenals contain, in addition to ouabain, a second inhibitor of the sodium pump. J Biol Chem 1998; 273: 784-792
25. Kawamura A, Guo J, Itagaki Y et al. On the structure of endogenous ouabain. Proc Natl Acad Sci 1999; 96: 6654-6659
26. Goto A, Ishiguro T, Yamada K et al. Isolation of an urinary digitalis-like factor indistinguishable from digoxin. Biochem Biophys Res Commun 1990; 173: 1093-1101
27. +-ATPase inhibitor in patients after acute myocardial infarction. Hypertension 1998; 31: 1097-1103
28. Yoshika M, Komiyama Y, KonishiMet al. Novel digitalis-like factor, marinobufotoxin, isolated from cultured Y-1 cells, and its hypertensive effect in rats. Hypertension 2007; 49: 209-214
29. Komiyama Y, Dong XH, Nishimura N et al. A novel endogenous digitalis, telocinobufagin, exhibits elevated plasma levels in patients with terminal renal failure. Clin Biochem 2005; 38: 36-45
30. Lichtstein D, Gati I, Samuelov S et al. Identification of digitalis-like compounds in human cataractous lenses. Eur J Biochem 1993; 216: 261-268
31. Sich B, Kirch U, Tepel M et al. Pulse pressure correlates with a proscillaridin A immunoreactive compound. Hypertension 1996; 27: 1073-1078
32. D'Urso G, Frascarelli S, Balzan S et al. Production of ouabain-like factor in normal and ischemic rat heart. J Cardiovasc Pharmacol 2004; 53: 657-662
33. Komiyama Y, Nishimura N, Munakata M et al. Identification of endogenous ouabain in culture supernatant of PC12 cells. J Hypertens 2001; 19: 229-236
34. Murrell JR, Randall JD, Rosoff J et al. Endogenous ouabain. Upregulation of steroidogenic genes in hypertensive hypothalamus but not adrenal. Circulation 2005; 112: 1301-1308
35. Laredo J, Hamilton JP, Hamlyn JM. Secretion of endogenous ouabain from bovine adrenal cells. Role of zona glomerulosa and zona fasciculata. Biochem Biophys Res Commun 1995; 212: 487-493
36. Qazzaz HMAM, Cao Z, Bolanowski DD et al. De novo biosynthesis and radiolabeling of mammalian digitalis-like factors. Clin Chem 2004; 50: 612-620
37. Gärtner DE, Keilholz W, Seitz H-U. Purification, characterization and partial peptide microsequencing of progesterone 5beta-reductase from shoot cultures of Digitalis purpurea. Eur J Biochem 1994; 225: 1125-1132
38. Charbonneau A, The V. Genomic organization of a human 5beta-reductase and its pseudogene and substrate selectivity of the expressed enzyme. Biochim Biophys Acta 2001; 1517: 228-235
39. 4-3-ketosteroid 5β-reductase. J Biol Chem 1984; 259: 7519-7524
40. Dmitrieva RI, Bagrov AY, Lalli E et al. Mammalian bufadienolide is synthesized from cholesterol in the adrenal cortex by a pathway that is independent of cholesterol side-chain cleavage. Hypertension 2000; 36: 442-448
41. Huang BS, Amin MS, Leenen FHH. The central role of the brain in salt-sensitive hypertension. Curr Opin Cardiol 2006; 21: 295-304
42. Bagrov AY, Fedorova OV. Cardenolide and bufadienolide ligands of the sodium pump. How they work together in NaCl sensitive hypertension. Front Biosci 2005; 10: 2250-2256.
43. Wang JG, Staessen JA, Messagio E et al. Salt, endogenous ouabain and blood pressure interactions in the general population. J Hypertens 2003; 2003: 1475-1481
44. Manunta P, Hamilton BP, Hamlyn JM. Salt intake and depletion increase circulating levels of endogenous ouabain in normal men. Am J Physiol Regul Integr Comp Physiol 2006; 290: R553-R559
45. Laredo J, Hamilton BP, Hamlyn JM. Ouabain is secreted by bovine adrenocortical cells. Endocrinology 1994; 135: 794-797
46. Laredo J, Shah JR, Lu Z et al. Angiotensin II stimulates secretion of endogenous ouabain from bovine adrenal cortical cells via angiotensin II receptors. Hypertension 1997; 29: 401-407
47. Laredo J, Shah JR, Hamilton BP et al. Alpha-1 adrenergic receptors stimulate secretion of endogenous ouabain from human and bovine adrenocortical cells. In Taniguchi K, Kayas S (eds). Na/K-ATPase and Related ATPases. Amsterdam: Elsevier, 2000; 671-679
48. Fedorova OV, Anderson DE, Bagrov AY. Plasma marinobufagenin-like and ouabain-like immunoreactivity in adrenocorticotropin-treated rats. Am J Hypertens 1998; 11: 796-802
49. Amin M, Wang H, Reza E et al. Distribution of epithelial sodium channels and mineralocorticoid receptors in cardiovascular regulatory centers in rat brain. Am J Physiol Regul Integr Comp Physiol 2005; 289: R1787-R1797
50. Fedorova OV, Zhuravin IA, Agalakova NI et al. Intrahippocampal microinjection of an exquisitely low dose of ouabain mimics NaCl loading and stimulates a bufadienolide Na/K-ATPase inhibitor. J Hypertens 2007; 25: 1834-1844
51. Bauer N, Müller-Ehmsen J, Krämer U et al. Ouabain-like compound changes rapidly upon physical exercise in man and dog - effects of b-blockade and ACE-inhibition. Hypertension 2005; 45: 1024-1028
52. +-ATPase from midbrain and adrenal. Am J Physiol 1998; 274: F182-F188
53. Fedorova OV, Anderson DE, Lakatta EG et al. Interaction of NaCl and behavioral stress on endogenous sodium pump ligands in rats. Am J Physiol Regul Integr Comp Physiol 2001; 281: R352-R358
54. Weidemann H, Salomon N, Avnit-Sagi T et al. Diverse effects of stress and additional adrenocorticotropic hormone on digitalis-like compounds in normal and nude mice. J Neuroendocrinol 2004; 16: 1-6
55. Hamlyn JM, Lu Z, Manunta P et al. Observations on the nature, biosynthesis, secretion and significance of endogenous ouabain. Clin Exp Hypertens 1998; 20: 523-533
56. Komiyama Y, Nishimura N, Munakata M et al. Increases in plasma ouabainlike immunoreactivity during surgical extirpation of pheochromocytoma. Hypertens Res 1999; 22: 135-139
57. Manunta P, Evans G, Hamilton BP et al. A new syndrome with elevated plasma ouabain and hypertension secondary to an adrenocortical tumor. J Hypertens 1992; 10: S27
58. +-ATPase inhibitor from rat brain. Am J Physiol 1988; 254: F912-F917
59. Kennedy DJ, Vetteth S, Periyasamy SM et al. Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy. Hypertension 2006; 47: 488-495
60. Fedorova OV, Lakatta EG, Bagrov AY. Endogenous Na,K pump ligands are differentially regulated during acute NaCl loading of DAHL rats. Circulation 2000; 102: 3009-3014
61. Kennedy D, Malhotra D, Shapiro J. Molecular insights into uremic cardiomyopathy: cardiotonic steroids and Na/K ATPase signaling. Cell Mol Biol (Noisy-le-grand) 2006; 52: 3-14
62. Elkareh J, Kennedy DJ, Yashaswi B et al. Marinobufagenin stimulates fibroblast collagen production and causes fibrosis in experimental uremic cardiomyopathy. Hypertension 2007; 49: 215-224
63. 2-isoform of Na-K-ATPase mediates ouabain-induced hypertension in mice and increased vascular contractility in vitro. Am J Physiol Heart Circ Physiol 2005; 288: H477-H485
64. Blanco G, Mercer RW. Isozymes of the Na-K-ATPase: heterogeneity in structure, diversity in function. Am J Physiol 1998; 275: F633-F650
65. 1 when expressed separately in yeast cells. Am J Physiol Cell Physiol 2001; 281: C1355-C1364
66. Crambert G, Schaer D, Roy S et al. New molecular determinants controlling the accessibility of ouabain to its binding site in human Na,K-ATPase a isoforms. Mol Pharmacol 2004; 65: 335-341
67. +-ATPase and biological significance of their cardiac glycoside binding site. Am J Physiol Regul Integr Comp Physiol 2006; 290: R524-R528
68. Dostanic-Larson I, Van Huysse JW, Lorenz JN et al. The highly conserved cardiac glycoside binding site of Na, K-ATPase plays a role in blood pressure regulation. PNAS 2005; 102: 15845-15850
69. +-ATPase as a signal inducer. Eur J Biochem 2002; 269: 2434-2439
70. Fedorova OV, Kolodkin NI, Agalakova NI et al. Marinobufagenin, an endogenous a-1 sodium pump ligand, in hypertensive Dahl salt-sensitive rats. Hypertension 2001; 37: 462-466
71. Kennedy DJ, Vetteth S, Xie M et al. Ouabain decreases sarcoplasmic reticulum calcium ATPase (SERCA2a) activity in rat hearts by a process involving protein oxidation Am J Physiol Heart Circ Physiol 2006; 291: H3003-H3011
72. Rossi GP, Manunta P, Hamlyn JM et al. Immunoreactive endogenous ouabain in primary hyperaldosteronism and essential hypertension: relationship with plasma renin, aldosterone and blood pressure levels. J Hypertens 1995; 13: 1181-1191
73. + pump inhibitor purified from human urine. Eur J Biochem 1987; 162: 129-135
74. Manunta P, Iacoviello M, Forleo C et al. High circulating levels of endogenous ouabain in the offspring of hypertensive and normotensive individuals. J Hypertens 2005; 23: 1677-1681
75. Pitzalis MV, Hamlyn JM, Messaggio E et al. Independent and incremental prognostic value of endogenous ouabain in idiopathic dilated cardiomyopathy. Eur J Heart Fail 2006; 8: 179-186
76. Kaide JI, Ura N, Torii T et al. Effect of digoxin-specific antibody fab fragment (Digibind) on blood pressure and renal water. Sodium metabolism in 5/6 reduced renal mass hypertensive rats. Am J Hypertens 1999; 12: 611-619
77. Pullen MA, Brooks DP, Edwards RM. Characterization of the neutralizing activity of digoxin-specific fab toward ouabain-like steroids. J Pharmacol Exp Ther 2004; 310: 319-325
78. Averina I, Tapilskaya N, Reznik V et al. Endogenous Na/K-ATPase inhibitors in patients with preeclampsia. Cell Mol Biol (Noisy-le-grand) 2006; 52: 19-23
79. Menezes JC, Dichtchekenian V. Digoxin antibody prevents cerebral hemorrhage-induced hypertension. Am J Hypertens 2003; 16: 1062-1065
80. Huang BS, Harmsen E, Yu H et al. Brain ouabain-like activity and the sympathoexcitatory and pressor effects of central sodium in rats. Circ Res 1992; 71: 1059-1066
81. Fedorova OV, Doris PA, Bagrov AY. Endogenous marinobufagenin-like factor in acute volume expansion. Clin Exp Hypertens 1998; 20: 581-591
82. Bagrov AY, Feodorova OV, Dmitrieva RI et al. Plasma marinobufagenin-like and ouabain-like immunoreactivity during saline volume expansion in anaesthetized dogs. Cardiovasc Res 1996; 31: 296-305
83. Vu H, Ianosi-Irimie M, Pridjian C et al. Involvement of marinobufagenin in a rat model of human preeclampsia. Am J Nephrol 2005; 25: 520-528
84. Kennedy DJ, Omran E, Periyasamy SM et al. Effect of chronic renal failure on cardiac contractile function, calcium cycling, and gene expression of proteins important for calcium homeostasis in the rat. J Am Soc Nephrol 2003; 14: 90-97
85. Fedorova OV, Talan MI, Agalakova NI et al. Endogenous ligand of a sodium pump, marinobufagenin, is a novel mediator of sodium chloride dependent hypertension. Circulation 2002; 105: 1122-1127
86. Fedorova OV, Kolodkin NI, Agalakova NI et al. Antibody to marinobufagenin lowers blood pressure in pregnant rats on a high NaCl intake. J Hypertens 2005; 23: 835-842
87. Periyasamy SM, Liu J, Tanta F et al. Salt loading includes redistribution of the plasmalemmal Na/K-ATPase in proximal tubule cells. Kidney Int 2005; 67: 1868-1877
88. Liu J, Shapiro JI. Regulation of sodium pump endocytosis by cardiotonic steroids: molecular mechanisms and physiological implications. Pathophysiology 2007; 14: 171-181
89. Fedorova OV, Agalakova NI, Morrell CH et al. ANP differentially modulates marinobufagenin-induced sodium pump inhibition in kidney and aorta. Hypertension 2006; 48: 1160-1168
90. Thomas W, McEneaney V, Harvey B. Aldosterone-induced signalling and cation transport in the distal nephron. Steroids 2008; 73: 979-984
91. Mick V, Itani O, Loftus R et al. The alpha-subunit of the epithelial sodium channel is an aldosterone-induced transcript in mammalian collecting ducts, and this transcriptional response is mediated via distinct cis-elements in the 5′-flanking region of the gene. Mol Endocrinol 2001; 15: 575-588
92. Kolla V, Litwack G. Transcriptional regulation of the human Na/K ATPase via the human mineralocorticoid receptor. Mol Cell Biochem 2000; 204: 35-40
93. Smith C, He Q, Huang L et al. Marinobufagenin interferes with the function of the mineralocorticoid receptor. Biochem Biophys Res Commun 2007; 356: 930-934
94. Gheorghiade M, Ferguson D. Digoxin: a neurohormone modulator in heart failure? Circulation 1991; 84: 2181-2186
95. Huang BS, Kudlac M, Kumarathasan R et al. Digoxin prevents ouabain and high salt intake-induced hypertension in rats with sinoaortic denervation. Hypertension 1999; 34: 733-738
96. Kennedy D, Elkareh J, Shidyak A et al. Partial nephrectomy as a model for uremic cardiomyopathy in the mouse. Am J Physiol Renal Physiol 2008; 294: F450-F454
97. Gottlieb SS, Rogowski AC, Weinberg M et al. Elevated concentrations of endogenous ouabain in patients with congestive heart failure. Circulation 1992; 86: 420-425
98. Manunta P, Hamilton J, Rogowski AC et al. Chronic hypertension induced by ouabain but not digoxin in the rat: antihypertensive effect of digoxin and digitoxin. Hypertens Res 2000; 23: S77-S85